clinical trial · NCT05780515
A Study of ANX009 in Adult Participants With Lupus Nephritis
Lupus NephritisANX009
brief summary
The main purpose of this study is to determine the safety and tolerability of repeat doses of ANX009 in participants with lupus nephritis (LN).
started
Aug 9, 2022
primary completion
Aug 31, 2023
completion
Oct 31, 2023
last updated
Aug 22, 2024
detailed description
All participants may continue to receive stable background standard of care therapy for LN and systemic lupus erythematosus (SLE) as permitted by the protocol (for example, mycophenolate mofetil \[MMF\], azathioprine, antimalarials, glucocorticoids, cyclosporin, voclosporin, tacrolimus, angiotensin converting enzyme \[ACE\] inhibitors, angiotensin receptor blockers \[ARBs\]).
official title
A Single-Arm, Phase 1b, Open-Label Study to Assess the Safety, Tolerability, and Pharmacodynamics of Repeat-Doses of Subcutaneous ANX009 With Standard of Care Therapy in Adult Participants With Lupus Nephritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol